1. Home
  2. PBYI vs EVE Comparison

PBYI vs EVE Comparison

Compare PBYI & EVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • EVE
  • Stock Information
  • Founded
  • PBYI 2010
  • EVE 2021
  • Country
  • PBYI United States
  • EVE United States
  • Employees
  • PBYI N/A
  • EVE N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • EVE Blank Checks
  • Sector
  • PBYI Health Care
  • EVE Finance
  • Exchange
  • PBYI Nasdaq
  • EVE Nasdaq
  • Market Cap
  • PBYI 176.1M
  • EVE 159.3M
  • IPO Year
  • PBYI N/A
  • EVE 2021
  • Fundamental
  • Price
  • PBYI $2.50
  • EVE $11.00
  • Analyst Decision
  • PBYI Strong Buy
  • EVE
  • Analyst Count
  • PBYI 1
  • EVE 0
  • Target Price
  • PBYI $7.00
  • EVE N/A
  • AVG Volume (30 Days)
  • PBYI 330.8K
  • EVE 12.8K
  • Earning Date
  • PBYI 10-31-2024
  • EVE 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • EVE N/A
  • EPS Growth
  • PBYI N/A
  • EVE 4067.26
  • EPS
  • PBYI 0.18
  • EVE 0.24
  • Revenue
  • PBYI $219,143,000.00
  • EVE N/A
  • Revenue This Year
  • PBYI N/A
  • EVE N/A
  • Revenue Next Year
  • PBYI N/A
  • EVE N/A
  • P/E Ratio
  • PBYI $13.95
  • EVE $45.01
  • Revenue Growth
  • PBYI N/A
  • EVE N/A
  • 52 Week Low
  • PBYI $2.13
  • EVE $10.63
  • 52 Week High
  • PBYI $7.73
  • EVE $12.03
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 42.87
  • EVE 45.03
  • Support Level
  • PBYI $2.45
  • EVE $10.97
  • Resistance Level
  • PBYI $2.63
  • EVE $11.07
  • Average True Range (ATR)
  • PBYI 0.14
  • EVE 0.07
  • MACD
  • PBYI 0.06
  • EVE -0.00
  • Stochastic Oscillator
  • PBYI 65.85
  • EVE 75.51

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About EVE EVe Mobility Acquisition Corp

EVe Mobility Acquisition Corp is a blank check company.

Share on Social Networks: